BIOCON receives nod from DCGI for BIOMAb EGFR®

DCGI has granted approval for the marketing of BIOMAb EGFR® in the Indian market. The product will first be used in the treatment of head and neck cancers and later extended to other indications viz. Colorectal, Brain, Breast, Pancreatic and Lung cancers. This will be the first proprietary product to be marketed by the Company. This demonstrates the success of the Company´s innovation led strategy.

Source : Equity Bulls

Keywords